Infographic: Providers’ picksWhat are the OTC products most recommended by pharmacy clinicians? Our new survey lists the top picks across 12 categories. GSK to acquire Bellus HealthThe acquisition provides GSK access to Camlipixant, a P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC. J&J’s Janssen releases new dosing strength for Erleada The move allows prescribers the flexibility to prescribe one 240 mg tablet or four 60 mg tablets once daily based on patient needs. Emergent BioSolutions receives FDA OK for OTC Narcan Nasal Spray Narcan Naloxone HCl Nasal Spray 4 mg is the first and only spray to receive over-the-counter status in the United States. FDA advisory committee votes in support of Pfizer’s Paxlovid The committee voted 16 to 1 that available data support the safety and effectiveness of Paxlovid for treating mild to moderate COVID-19 in adult patients at high risk for progression to severe illness. Pfizer to acquire Seagen for $43B Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Reata receives FDA OK for Skyclarys Skyclarys is used for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older. Pfizer receives FDA OK for Zavzpret Zavzpret is the first and only calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine in adults. FDA OKs Kevzara Kevzara is the first and only biologic indicated for patients with polymyalgia rheumatica. Walgreens issues statement on policy regarding abortion pill Several politicians and the Biden administration have issued statements regarding Walgreens’ policy on the abortion pill. First Previous 6 7 8 9 10 Next Last